BR112022017425A2 - Usos terapêuticos de compostos macrocíclicos - Google Patents

Usos terapêuticos de compostos macrocíclicos

Info

Publication number
BR112022017425A2
BR112022017425A2 BR112022017425A BR112022017425A BR112022017425A2 BR 112022017425 A2 BR112022017425 A2 BR 112022017425A2 BR 112022017425 A BR112022017425 A BR 112022017425A BR 112022017425 A BR112022017425 A BR 112022017425A BR 112022017425 A2 BR112022017425 A2 BR 112022017425A2
Authority
BR
Brazil
Prior art keywords
therapeutic uses
macrocyclic compounds
compounds
mammals
compositions
Prior art date
Application number
BR112022017425A
Other languages
English (en)
Inventor
William Murray Brion
Zhai Dayong
J Cui Jingrong
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of BR112022017425A2 publication Critical patent/BR112022017425A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

USOS TERAPÊUTICOS DE COMPOSTOS MACROCÍCLICOS. Essa revelação está relacionada ao uso de certos compostos de diaril macrociclo no tratamento de doença em mamíferos. Essa revelação também está relacionada às composições que incluem esses compostos, e aos métodos de utilização dessas composições no tratamento de doenças em mamíferos, especialmente em humanos.
BR112022017425A 2020-03-02 2021-03-01 Usos terapêuticos de compostos macrocíclicos BR112022017425A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062984159P 2020-03-02 2020-03-02
PCT/US2021/020255 WO2021178296A1 (en) 2020-03-02 2021-03-01 Therapeutic uses of macrocyclic compounds

Publications (1)

Publication Number Publication Date
BR112022017425A2 true BR112022017425A2 (pt) 2022-11-29

Family

ID=77613771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017425A BR112022017425A2 (pt) 2020-03-02 2021-03-01 Usos terapêuticos de compostos macrocíclicos

Country Status (10)

Country Link
EP (1) EP4114530A4 (pt)
JP (1) JP2023515687A (pt)
KR (1) KR20230022151A (pt)
CN (1) CN115397514A (pt)
AU (1) AU2021229457A1 (pt)
BR (1) BR112022017425A2 (pt)
CA (1) CA3174455A1 (pt)
IL (1) IL295938A (pt)
MX (1) MX2022010945A (pt)
WO (1) WO2021178296A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116829562A (zh) * 2021-02-10 2023-09-29 深圳国顺康医药科技有限公司 一种巨环化合物、药物组合物以及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
KR102623734B1 (ko) * 2015-07-06 2024-01-10 터닝 포인트 테라퓨틱스, 인크. 디아릴 매크로사이클 다형체
TW201815799A (zh) * 2016-07-28 2018-05-01 美商Ｔｐ生物醫藥公司 巨環激酶抑制劑
CA3069232A1 (en) * 2017-07-28 2019-01-31 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
KR20230022151A (ko) 2023-02-14
AU2021229457A1 (en) 2022-10-20
MX2022010945A (es) 2022-10-07
CA3174455A1 (en) 2021-09-10
CN115397514A (zh) 2022-11-25
IL295938A (en) 2022-10-01
JP2023515687A (ja) 2023-04-13
EP4114530A1 (en) 2023-01-11
WO2021178296A1 (en) 2021-09-10
EP4114530A4 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
MX2018000718A (es) Macrociclos de diarilo quirales y usos de los mismos.
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
EA200701113A1 (ru) Макролиды
ECSP056138A (es) Dihidroquinazolinas sustituidas
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
CO2021005226A2 (es) Nuevos compuestos antihelmínticos
BR112015013700A2 (pt) composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
UY31958A (es) Nucleosidos y nucleotidos bicilicos como agentes terapeuticos
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
BRPI0815708B8 (pt) composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
BR112014031394A8 (pt) Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
UY28130A1 (es) Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso.
CL2021003098A1 (es) Compuestos inmunomoduladores diméricos contra mecanismos basados en cereblon (divisional de la solicitud no. 202100061)
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112022023025A2 (pt) Moduladores de htt para tratar doença de huntington
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis